FDA puts the brakes on a rare disease biotech’s PhIII as regulators wait for an update — shares crumble

Submitted by admin on September 23, 2019 - 10:41am

Source:

Endpoints

News Tags:

Abeona Therapeutics

clinical trials

EB-101

recessive dystrophic epidermolysis bullosa

FDA

Headline:

FDA puts the brakes on a rare disease biotech’s PhIII as regulators wait for an update — shares crumble

snippet:

Little Abeona Therapeutics $ABEO is back in trouble this morning.

The biotech reported that the FDA is slamming the brakes on their Phase III study of EB-101 for rare cases of recessive dystrophic epidermolysis bullosa, which is characterized by fragile skin that blisters quickly.

Search form

You are here

FDA puts the brakes on a rare disease biotech’s PhIII as regulators wait for an update — shares crumble

FDA puts the brakes on a rare disease biotech’s PhIII as regulators wait for an update — shares crumble